File(s) not publicly available

Reason: No enhanced material

Abaloparatide: First Global Approval

online resource
posted on 28.03.2018 by Matt Shirley
Disclosure: The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis, Springer SBM.

Additional information about this AdisInsight Report can be found here.

Abstract

Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius Health as an osteoanabolic agent for the treatment of postmenopausal osteoporosis. Abaloparatide acts through selective activation of the parathyroid hormone type 1 receptor signalling pathway. In April 2017, subcutaneous abaloparatide received its first global approval, in the USA, for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture, or who have failed or are intolerant to other available osteoporosis therapy. The drug is in preregistration for this indication in the EU. Radius is also developing a transdermal formulation of abaloparatide, with administration via a microneedle patch. This article summarizes the milestones in the development of abaloparatide leading to this first approval for the treatment of women with postmenopausal osteoporosis. Access to the full article can be found here.

© Springer International Publishing AG, part of Springer Nature 2017

History

Exports

Logo branding

Categories

Exports